GENE ONLINE|News &
Opinion
Blog

2021-10-05| Special

Taiwan’s Biotech Industry, Lackluster or Late Bloomer? A Breakdown of Policies, Hotspots, and Market Movements

by Kathy Huang
Share To
In this special series, we review the evolution of Taiwan’s biotech industry, focusing on key policies, bioclusters as well as the major deals surrounding licensing, mergers, and acquisitions. In the forthcoming articles, we will also present industry overviews, company analyses, and biotech investor interviews to depict the current landscape and predict future directions.

In the past, Taiwan built its ICT industry as a service provider which international brands could outsource. It can take a similar approach with its burgeoning CDMO industry to accumulate experience and technical knowledge. When considering manufacturing powerhouses such as South Korea and India, which have already established their CDMO markets, Taiwan’s industrial-scale...

GO Prime with only $1.49 now

LATEST
Novel RAGE Antagonist Stirs Hopes for Countering Diabetic Complications
2021-12-07
AstraZeneca Blocks Private Equity Buyout of Swedish Pharma Sobi
2021-12-06
Coherent Biopharma, WuXi STA Collab Takes a Crack at Peptide-Drug Conjugates
2021-12-06
How CDMOs are Restructuring the Biopharma Landscape – An Interview with Bobby Sheng
2021-12-06
BeiGene launches IPO on Shanghai’s STAR market to raise $3B
2021-12-03
Novartis, UCB Take Aim at Parkinson’s Disease Under $1.65 Billion Collab
2021-12-03
Atara Biotherapeutics’ First-In-Class Allogeneic T-Cell Therapy Accepted for EMA Review
2021-12-02
EVENT
2021-12-13
63rd ASH ANNUAL MEETING AND EXPOSITION
Georgia, USA
2021-12-28
BIOHK2021
Hong Kong, China
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!